Drug
HBM9161 clinical trials
Also written IMVT-1401, Batoclimab and RVT-1401.
- studies test it
- 18
- open now
- 0
- in phase 3
- 8
- first study started
- 2019
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
18 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
Immunovant Sciences GmbH (11) · Harbour BioMed (Guangzhou) Co. Ltd. (7)
Studies
Open first, then newest update. How each study uses HBM9161 is read from its arms, and is right about nine times in ten.
Testing it · 18
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia GravisTerminatedPhase 3Immunovant Sciences GmbHNCT05403541Written as Batoclimab 680 mg SC weekly
- A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' DiseaseCompletedPhase 2Immunovant Sciences GmbHNCT05907668Written as IMVT-1401 (batoclimab)
- To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPTerminatedPhase 2Immunovant Sciences GmbHNCT05581199Written as Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
- An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)TerminatedPhase 2Immunovant Sciences GmbHNCT07188844Written as Batoclimab
- Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseaseTerminatedPhase 3Immunovant Sciences GmbHNCT05517447Written as Batoclimab
- Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisCompletedPhase 3Harbour BioMed (Guangzhou) Co. Ltd.NCT05332210Written as HBM9161 Injection (680mg)
- A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITPCompletedPhase 2/3Harbour BioMed (Guangzhou) Co. Ltd.NCT04428255Written as HBM9161 Dose A
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseCompletedPhase 3Immunovant Sciences GmbHNCT05524571Written as Batoclimab
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseCompletedPhase 3Immunovant Sciences GmbHNCT05517421Written as Batoclimab
- A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsCompletedPhase 2Immunovant Sciences GmbHNCT03863080Written as RVT-1401
- Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG PatientsCompletedPhase 3Harbour BioMed (Guangzhou) Co. Ltd.NCT05039190Written as HBM9161 Injection (680mg)
- A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG PatientsCompletedPhase 2Harbour BioMed (Guangzhou) Co. Ltd.NCT04346888Written as HBM9161 Injection (680mg and 340 mg)
- ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )TerminatedPhase 2Immunovant Sciences GmbHNCT03938545Written as RVT-1401 (Administered via subcutaneous injection)
- To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).TerminatedPhase 2Immunovant Sciences GmbHNCT04253236Written as RVT-1401 680 mg/weekly
- A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye DiseaseStatus unknownPhase 2/3Harbour BioMed (Guangzhou) Co. Ltd.NCT05015127Written as HBM9161 680 mg qw by q2w from week 13
- A Study of HBM9161 in NMOSD PatientsCompletedPhase 1Harbour BioMed (Guangzhou) Co. Ltd.NCT04227470Written as HBM9161 Injection
- Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)CompletedPhase 2Immunovant Sciences GmbHNCT03922321Written as RVT-1401
- A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese VolunteersCompletedPhase 1Harbour BioMed (Guangzhou) Co. Ltd.NCT03971916Written as HBM9161(HL161BKN)